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Abstract
Background: Developing analytical methodologies to identify biomarkers in easily accessible body fluids is highly valuable
for the early diagnosis and management of cancer patients. Peripheral whole blood is a ‘‘nucleic acid-rich’’ and
‘‘inflammatory cell-rich’’ information reservoir and represents systemic processes altered by the presence of cancer cells.
Methodology/Principal Findings: We conducted transcriptome profiling of whole blood cells from melanoma patients. To
overcome challenges associated with blood-based transcriptome analysis, we used a PAXgene
TM tube and NuGEN
Ovation
TM globin reduction system. The combined use of these systems in microarray resulted in the identification of 78
unique genes differentially expressed in the blood of melanoma patients. Of these, 68 genes were further analyzed by
quantitative reverse transcriptase PCR using blood samples from 45 newly diagnosed melanoma patients (stage I to IV) and
50 healthy control individuals. Thirty-nine genes were verified to be differentially expressed in blood samples from
melanoma patients. A stepwise logit analysis selected eighteen 2-gene signatures that distinguish melanoma from healthy
controls. Of these, a 2-gene signature consisting of PLEK2 and C1QB led to the best result that correctly classified 93.3%
melanoma patients and 90% healthy controls. Both genes were upregulated in blood samples of melanoma patients from
all stages. Further analysis using blood fractionation showed that CD45
2 and CD45
+ populations were responsible for the
altered expression levels of PLEK2 and C1QB, respectively.
Conclusions/Significance: The current study provides the first analysis of whole blood-based transcriptome biomarkers for
malignant melanoma. The expression of PLEK2, the strongest gene to classify melanoma patients, in CD45
2 subsets
illustrates the importance of analyzing whole blood cells for biomarker studies. The study suggests that transcriptome
profiling of blood cells could be used for both early detection of melanoma and monitoring of patients for residual disease.
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Introduction
Malignant melanoma is the most aggressive form of skin cancer,
and the fifth and seventh most common cancer in men and women
in the USA, respectively [1]. The American Cancer Society
estimates that 68,130 new melanoma cases will be diagnosed and
8,700 people will die from melanoma in the USA in 2010 [1].
Because systemic therapies for advanced melanoma have limited
efficacy, early detection and accurate staging of melanoma
remains the mainstay of curative treatment of melanoma.
Genome-wide gene expression profiling has been used to better
classify many cancers [2,3] and to understand the molecular
pathways involved in diverse disease processes [4,5,6,7,8,9].
Affymetrix microarrays have been extensively used to obtain gene
expression profiles from human melanoma tissues and human
melanoma cells [10,11,12,13,14,15,16,17,18,19,20,21]. However,
obtaining fresh cancer cells and tissues from cancer patients for
laboratory analysis is sometimes challenging for primary tumor
whose lesion is usually small and whose entire lesion needs to be
formalin-fixed for accurate diagnosis and staging. Therefore,
developing analytical methodologies to detect and identify
biomarkers in easily accessible body fluids such as peripheral
blood would be highly valuable for the early diagnosis and
management of cancer patients [22].
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matory cell-rich’’ information reservoir. Anti-tumor responses are
frequently observed in the blood of cancer patients whereas
immune systems often facilitate tumor progression by sculpting the
immunogenic phenotype of tumors (immunoediting) and by
secreting cytokines and inflammatory elements, proteases and
other extracellular matrix modulators [23,24,25,26,27]. In addi-
tion to immunocytes, peripheral blood of cancer patients contains
circulating tumors cells, endothelial cells, and bone-marrow-
derived cells, all of which can be used as resources for molecular
biomarkers. We hypothesized that peripheral whole blood
represents systemic processes altered by the presence of cancer
cells in the tumor microenvironment and/or in the circulation,
and that analytical methodologies to detect phenotypic changes of
these cells in the blood will provide relevant biomarkers in cancer
patients.
Blood-based gene expression biomarkers have been investigat-
ed in various non-cancerous disease conditions such as autoim-
mune, infectious, and neurological diseases [7,8,28,29,30,31,32].
Blood transcript profiling has also been studied in human cancers
using peripheral blood mononuclear cells [33,34,35,36,37].
Furthermore, circulating T cells [38] and tumor cells [39,40]
isolated from blood have been investigated by gene expression
analysis in melanoma patients and malignant glioma patients
[41]. While these studies have provided valuable information on
blood cell-derived gene expression from cancer patients, the
information sometimes show variance due to the analysis of a
subpopulation of blood. Pre-analytical steps such as storing,
handling and isolation of blood may induce changes in gene
expression. Furthermore, multiple steps before analysis in
laboratories may hinder future application of biomarker studies
for multi-center clinical trials. Collecting whole blood cells
directly into a PAXgene
TM RNA stabilization tube instantly
stabilizes RNA, reduces process-related artifacts and has been
used to profile blood transcriptomes from colon and breast
cancer patients [42,43,44]. However, the abundance of globin
mRNA in whole blood RNA preparations interferes with
hybridization efficiency of non-globulin transcripts when per-
forming microarray analysis of whole blood cells, resulting in
reduced present calls and augmented variability in microarray
analysis [45]. Several methods have been developed to reduce the
impact of globin RNA including an Ambion GLOBINclear kit,
Affymetrix peptide nucleic acid methodology and NuGEN
Ovation
TM technology [46,47,48].
In the present study, we used the PAXgene
TM RNA stabilization
tube to instantly stabilize RNA from whole blood. We also used
biotinylated probes from the NuGEN Ovation
TM Whole Blood
Solution to amplify non-globin RNA without the impact of globin
RNA for microarray analysis. The combined use of these systems
resulted in the identification of unique genes differentially expressed
in the blood of melanoma patients. Genes selected from microarray
analysis were verified by high-throughput quantitative reverse
transcriptase PCR (qRT-PCR) analysis and 39 genes were confirmed
to be expressed in melanoma blood. A stepwise logit analysis selected
eighteen 2-gene signatures that distinguish melanoma from healthy
controls. Of these, a 2-gene signature consisting of PLEK2 and
C1QB led to the best result that correctly classified 93.3% melanoma
patients and 90% healthy controls. Both genes were upregulated even
in blood samples from stage I and II melanoma patients. Further
analysis using blood fractionation showed that CD45
2 and CD45
+
populations were responsible for the altered expression levels of
PLEK2 and C1QB, respectively, indicating the importance of
analyzing whole blood cells for blood-based biomarker studies
of cancer.
Methods
Ethics statement
All blood samples were collected at the University of Colorado
Hospital. The study protocol was approved by the University of
Colorado Hospital Institutional Review Board (#05-0309). Written
informed consents were obtained from all participants who agreed to
serve as blood donors.
Patient samples
One hundred fifty-one blood samples were collected for this
study (69 from melanoma patients and 82 from healthy controls).
Of these 151 samples, 10 samples were used in microarray
analysis, 95 samples were used in high-throughput qRT-PCR
analysis, 6 samples were used to identify cell subsets in fractionated
blood samples and 40 samples were used to compare genes in
fractionated blood samples. Melanoma patients were primarily of
Caucasian descent, and blood samples from age- and sex-matched
control were obtained from healthy Caucasians. For the micro-
array analysis, whole blood samples were obtained from 4 newly
diagnosed melanoma patients (stage IV, without treatment) and 6
healthy individuals. For the high-throughput qRT-PCR analysis,
whole blood samples were collected from 45 newly diagnosed
melanoma patients (stage I to IV) and 50 healthy individuals. Of
the 45 melanoma patients, 5 were diagnosed with stage I
melanoma, 8 were diagnosed with stage II melanoma, 11 were
diagnosed with stage III melanoma and 21 were diagnosed with
stage IV melanoma. For the analysis of fractionated samples to
identify cell subsets responsible for the expression of genes,
heparin-treated blood samples were obtained from 6 healthy
control subjects. For the analysis of fractionated samples to
compare genes, heparin-treated blood samples were obtained from
20 newly diagnosed melanoma patients and 20 healthy control
subjects. Of the 20 melanoma patients, 8 were diagnosed with
stage I melanoma, 3 were diagnosed with stage II melanoma, 3
were diagnosed with stage III melanoma and 6 were diagnosed
with stage IV melanoma. Blood samples were collected with the
written informed consent of patients under IRB approved
protocols and adhering to HIPAA regulations.
Whole blood collection and RNA isolation
Whole blood samples were collected into a PAXgene
TM RNA
stabilization tube (PreAnalytiX, Hombrechtikon, CH) (2.5 ml).
The tube contains a nucleic acid preservative and provides a
means for collection, stabilization and transportation of a whole
blood cellular RNA specimen in a closed evacuated system. RNA
was extracted from the samples using a PAXgene
TM Blood RNA
Kit (PreAnalytiX) in accordance with the manufacturer’s protocol.
Quality of the RNA was verified on an AgilentH 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA) and the quantity of RNA
was determined by NanoDropH ND-1000 spectrophotometer
(Thermo Scientific, Wilmington, DE).
Blood cell fractionation and RNA isolation
Fresh blood samples were collected using VacutainerH Heparin
Tubes (BD, Franklin Lakes, NJ) and kept on ice, followed by
labeling with MACS human CD45
+ microbeads (Miltenyi Biotec,
Auburn, CA). Briefly, whole blood (3 ml) was added with 150 ml
microbeads and incubated for 15 minutes at 4uC. Labeled cells
were washed and resuspended in autoMACS Running Buffer,
followed by separation with autoMAC
TM separator (Miltenyi
Biotec). Program ‘‘posseld2’’ and ‘‘depletes’’ were used to isolate
CD45-positive (CD45
+) and CD45-negative (CD45
2) cells,
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cells by Qiagen RNeasy mini kit (Qiagen, Valencia, CA).
Microarray hybridization
Total RNA (50 ng) from whole blood samples was amplified
using Ovation
TM Biotin RNA Amplification and Labeling System
V1 (NuGEN Technologies, San Carlos, CA) according to the
manufacturers’ instructions. Labeled cDNA was hybridized to
Affymetrix Human Genome U133 Plus 2.0 GeneChip oligonu-
ceotide arrays (54,000 probe sets, .47,000 transcripts) (Affyme-
trix, Santa Clara, CA). Hybridization signals were adjusted using
Affymetrix GenechipH Operating Software (GCOS) (version
1.1.1). GeneSpringGX version 10.0 (Agilent Technologies, Santa
Clara, CA) was used to analyze microarray data for hierarchical
clustering and significant pathways.
Quantitative RT-PCR (qRT-PCR) analysis
RNA from whole blood samples was analyzed for the expression
of 68 genes by high-throughput qRT-PCR whereas RNA from
fractionated samples was analyzed for the expression of 2 genes by
standard qRT-PCR.
High-throughput qRT-PCR was performed at Source MDx
(SMDx, Boulder, CO). Briefly, first strand cDNA was synthesized
from RNA by reverse transcription following priming with
random hexamers. Primer/probe reagents selected from the
microarray data were custom designed with the aid of Applied
Biosystems Primer ExpressH Software (Carlsbad, CA) following
SMDx proprietary design specifications. Precision profile melano-
ma microarray plates were manufactured using a high-throughput
BiomekH FX Laboratory Automation Workstation (Beckman
Coulter, Brea, CA) and the primer/probe sets of each target gene
of interest resided in triplicate wells. Rigorous quality control
testing ensured that amplification specificity and efficiency were
within defined limits. To carry out the assays, cDNA from samples
was added to the Precision Profile plates and high-throughput
qRT-PCR was performed. The intensity of released fluors was
measured as a function of time and compared with parallel
analysis to determine the background level. Each PCR reaction
contained primer/probe sets for the target gene and 18S RNA,
used as an internal control. The difference between the
fluorescence threshold cycle (CT) for the target and the internal
endogenous control (18S) was presented as a DCT value.
Standard qRT-PCR was performed at the University of Colorado
Denver. Fractionated cells were analyzed for the expression of PLEK2
and C1QB by standard qRT-PCR. Three pairs of primers were used:
PLEK2-F: 59-GTGCTCAAGGAGGGCTTC-39;P L E K 2 - R :5 9-GC-
TTGTAGTACACCAGCGTGTT-39;C 1 Q B - F :5 9-AAGGTGCC-
CGGTCTCTACTA-39;C 1 Q B - R :5 9-ACCTGGAAGGTGTTGT-
AGGC-39;G A P D H - F :5 9-TGCACCACCAACTGCTTAGC-39;G -
APDH-R: 59-GGCATGGACTGTGGTCATGAG-39.P C Ra m p l i -
fication and quantitation was performed using ABI SYBR Green
Master Mix (Applied Biosystems, Foster City, CA) and Stratagene
MX3000P
TM (Cedar Creek, Texas). GAPDH was used as an internal
control for normalization.
Statistical analysis
One-way ANOVA and logistic regression were used to evaluate
expression differences of high-throughput qRT-PCR between
melanoma patients and healthy controls. For one-way ANOVA,
statistical measures were determined using Enterprise Guide
version 2.05.89 (SAS Institute, Inc., Cary, NC). The Anderson-
Darling test and the Shapiro-Wilk test were used to determine
whether the gene expression data fit a normal distribution.
Student’s t-tests were performed to determine p-values and genes
were ranked in the order of significance using a one-WAY
ANOVA approach. Signature models distinguishing melanoma
patients from healthy control individuals were generated using an
automated search procedure in the program GOLDMineRH
(Graphical Ordinal Logit Displays based on Monotonic Regres-
sion) that implements a stepwise logit analysis for selecting the
predictor variables. All predictor genes were first ranked according
to their unique p-values. The most significant gene that
distinguished melanoma from healthy controls was first entered
into the logit analysis. Additional genes were added one step at a
time in a fast, stepwise inclusion algorithm process generated
models of prediction based on target genes assayed. Multiple
models were generated and evaluated based on goodness of
prediction (R
2, coefficient of determination). The cutoff of R
2
value was 0.6.
To evaluate expression levels of fractionated blood samples,
Student’s t-test was used. p-values of ,0.05 were considered
statistically significant.
Results
Identification of differentially expressed genes using
microarray
Whole blood samples from 4 newly diagnosed melanoma
patients (stage IV, without treatment) and 6 healthy individuals
were collected into PAXgene
TM RNA stabilization tubes. Isolated
RNA from the samples was of high quality with intact 18 s and
28 s ribosomal RNA and A260/280 of 2.1–2.2. Using Affymetrix
GeneChip U133A, we analyzed global gene expression changes in
blood samples from stage IV melanoma patients and healthy
individuals. A comparative analysis identified 997 significantly
altered transcripts (p,0.05, expression ratio .1.8 or 0.6).
Hierarchical cluster analysis of these genes showed clear
differences between melanoma patients and healthy individuals
(Fig. 1A). Differentially expressed genes were then subjected to
gene ontology analysis to identify biological processes (Fig. 1B).
The analysis revealed that multiple processes were significantly
altered in blood of melanoma patients compared with that from
healthy individuals (p,0.01). Many genes were associated with
cytoplasmic processes (78.7% of genes) and response to stimulus
(29.2%). Particularly, several immunological processes were
identified to be differentially expressed in blood samples from
melanoma patients including immune system process (17.7%),
immune response (17.7%), chemotaxis (7.2%), MHC class II
protein complex (4.7%), MHC protein complex (4.7%), MHC
class II receptor activity (4.3%) and antigen processing via MHC
class II (4.3%). Differentially expressed genes (997 genes) were also
subjected to significant pathway analysis, which identified three
significant (p,0.01) pathways: IL-4, Notch and Wnt (Fig. S1).
Selection of candidate genes by microarray analysis
We selected 78 candidate genes based on the criteria using fold
changes, expression levels and comparison replicates. Transcripts
shown in Fig. S2A (63 genes) were present above threshold level
(‘‘present’’ call, .10 ppm), had 1.8-fold or greater significant
differences between healthy control individuals and melanoma
patients, and had a high score by comparison replicates.
Transcripts shown in Fig. S2B had 5.5-fold or greater differences
between healthy individuals and melanoma patients. Most of the
candidate genes did not express high levels of transcripts, and the
top 15 genes were selected based on comparison replicates. Of the
78 selected genes, 46 were upregulated and 32 were downregu-
lated (Table S1). The gene list was submitted to SMDx for further
validation by high-throughput qRT-PCR.
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qRT-PCR analysis
High-throughput qRT-PCR was performed using whole blood
samples obtained from 45 newly diagnosed melanoma patients (stage
I to IV) and 50 healthy individuals (see Methods). Of the 78 selected
genes selected from microarray analysis, primers/probes of 68 genes
were custom designed at SMDx. Precision profile melanoma plates
were manufactured using the 68 genes and evaluated for their ability
to discriminate between healthy controls and melanomas. The order
of significance was ranked using a one-way ANOVA approach.
Thirty-nine genes (27 upregulated genes and 12 downregulated
genes) were confirmed to be differentially expressed in melanoma
blood compared with healthy control blood (Table 1). The analysis
yielded comparablep-values and comparable rankings of the genes in
terms of statistical significance.
Generation of signature models to distinguish melanoma
patients from healthy individuals
The genes confirmed by high-throughput qRT-PCR were
individually subjected to a stepwise logit analysis to select predictor
genes that distinguish melanoma from controls at the Statistical
Innovations. The analysis was performed using individual genes
demonstrating the best power to discriminate controls from
melanoma patients, as starting points. Additional genes were
added in a stepwise fashion until specificity/sensitivity reached the
75% criteria and R
2 value hit 0.6 cutoff (Table 2). Because the goal
of the present study was to generate signature models that were
simple enough to be translated into clinical practice, further genes
were not added once the criteria and cutoff were met. Of
significant importance is PLEK2 having the lowest p-value and a
high R
2 (0.56) that was already close to the cutoff value 0.6.
Indeed, PLEK2 as a single gene model, allowed 42/50 (84%)
controls and 38/45 (86.7%) melanoma patients to be classified
accurately (Table 3). Therefore, PLEK2 was chosen to be a
starting point (Table 2). The addition of the other gene resulted in
eighteen two-gene models that met the criteria and cutoff to
correctly discriminate melanoma patients and healthy control
individuals (Table 3). Among the above two-gene models, the
addition of C1QB led to the best result that correctly classified
93.3% (42/45) newly diagnosed melanoma patients and 90% (45/
50) healthy control individuals (Table 2, Table 3, Fig. 2A). Since
these genes were initially selected using microarray analysis of
blood samples from metastatic melanoma (stage IV) patients, we
investigated if the gene expression changes were detected in
samples from early stages of melanoma. As shown in Fig. 2B and
2C, both PLEK2 and C1QB were significantly upregulated even
in the blood of stage I/II patients, indicating their potential as a
blood-based biomarker in early diagnosis.
Identification of cell subsets responsible for the
expression of PLEK2 and C1QB by blood cell fractionation
The genes (PLEK2 and C1QB) identified in this study have not
been well investigated in cancer biology. Due to the nature of
biomarker discoveries using high-throughput methodologies and
whole blood analysis, the physiological relevance and biological
significance of these genes are unclear. Therefore, in order to
Figure 1. Microarray analysis of differentially expressed genes in melanoma. A. Hierarchical clustering of differentially expressed genes.
Whole blood samples were obtained from 4 newly diagnosed melanoma patients (stage IV, with no treatment, M1–M4) and 6 healthy control
individuals (C1–C6). Clustering of 1187 transcripts in blood from melanoma patients and healthy control individuals (p,0.05). Colored spots indicate
significant (p,0.05) upregulation (red) or downregulation (blue) of transcripts. Sample tree originated from the clustering of values with Euclidean
distance analyzed by GeneSpringGX 10.0. B. Gene ontology analysis of differentiated expressed genes (p,0.05) between melanoma patients and
healthy control individuals. Bar chart was drawn using gene ontology (p,0.01) tool from GeneSpringGX 10.0.
doi:10.1371/journal.pone.0020971.g001
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PLEK2 and C1QB, we analyzed cell subsets that are responsible
for the expression of these genes in the blood. Whole blood from 6
healthy control subjects was fractionated into leukocytes (white
blood cells) and non-leukocytes (erythrocytes, platelets and other
circulating cells) using human CD45 whole blood microbeads.
RNA from CD45
+ and CD45
2 cell subsets from healthy control
individuals were analyzed for the expression of PLEK2 and C1QB
by standard qRT-PCR at the University of Colorado Denver.
PLEK2 was found to be almost exclusively expressed in CD45
2
blood cells (Fig. 3, left panel). On the contrary, C1QB showed
higher expression levels in CD45
+ cells compared with CD45
2
Table 1. List of genes identified by microarray analysis and validated by high-throughput qRT-PCR.
Gene Symbol Gene Title
p-value
(microarray)
p-value
(qRT-PCR)
R2
(qRT-PCR)
Upregulated Genes
BLVRB Biliverdin reductase B (flavin reductase (NADPH)) 0.0322553 0.000087 0.14
BPGM 2,3-bisphosphoglycerate mutase 0.0351863 0.000029 0.1611
C1QB Complement component 1, q subcomponent, B chain 0.00673087 5.9E-08 0.2345
C20orf108 Chromosome 20 open reading frame 108 0.0001927 0.024 0.0504
CARD12 Caspase recruitment domain family, member 12 0.00647157 0.04 0.044
CHPT1 Choline phosphotransferase 1 0.0414433 0.0034 0.0863
F5 Coagulation factor V (proaccelerin, labile factor) 0.0349511 0.011 0.064
GLRX5 Glutaredoxin 5 homolog (S. cerevisiae) 0.00303576 0.00072 0.1095
GYPA Glycophorin A (MNS blood group) 0.00176843 0.018 0.0562
GYPB Glycophorin B (MNS blood group) 0.0104615 0.018 0.0556
IGF2BP2 Insulin-like growth factor 2 mRNA binding protein 2 0.0166351 6.5E-06 0.1788
IL1R2 Interleukin 1 receptor, type II 0.00972327 0.0026 0.0908
IRAK3 Interleukin-1 receptor-associated kinase 3 0.00052347 0.016 0.0599
LGALS3 Lectin, galactoside-binding, soluble, 3 (galectin 3) 0.0045688 0.00047 0.1164
NEDD4L Neural precursor cell expressed, developmentally down-regulated 4-like 0.0157874 2.5E-09 0.2787
NEDD9 Neural precursor cell expressed, developmentally down-regulated 9 0.0386422 0.009 0.0669
NUDT4 Nudix (nucleoside diphosphate linked moiety X)-type motif 4 0.00417398 0.000015 0.1684
PBX1 Pre-B-cell leukemia transcription factor 1 0.00458616 0.0052 0.0774
PLAUR Plasminogen activator, urokinase receptor 0.0351704 0.043 0.0419
PLEK2 Pleckstrin 2 0.00079183 4.2E-22 0.4979
PLXDC2 Plexin domain containing 2 0.00322457 5E-09 0.2637
SIAH2 Seven in absentia homolog 2 (Drosophila) 0.0006551 0.000003 0.1927
SLC4A1 Solute carrier family 4, anion exchanger, member 1 (erythrocyte
membrane protein band 3, Diego blood group)
0.0107523 0.000029 0.1548
TMOD1 Tropomodulin 1 0.00191409 0.0016 0.0959
TNS1 Tensin 1 0.0276222 0.013 0.0612
TSPAN5 Tetraspanin 5 0.0375013 0.0013 0.0998
XK X-linked Kx blood group (McLeod syndrome) 0.00753119 9.8E-07 0.2066
Downregulated Genes
CNKSR2 Connector enhancer of kinase suppressor of Ras 2 0.007204 0.000021 0.1681
EDIL3 EGF-like repeats and discoidin I-like domains 3 0.018857 0.00062 0.1113
INPP4B Inositol polyphosphate-4-phosphatase, type II, 105 kDa 0.000733 0.0042 0.084
KCNK2 Potassium channel, subfamily K, member 2 0.024077 3.8E-08 0.2452
LARGE Like-glycosyltransferase 0.000698 3.5E-06 0.1885
NBEA Neurobeachin 0.005041 0.000017 0.1677
NUCKS1 Nuclear casein kinase and cyclin-dependent kinase substrate 1 0.038581 0.007 0.0732
PTPRK Protein tyrosine phosphatase, receptor type, K 0.044927 0.000083 0.1473
SCAND2 SCAN domain containing 2 0.011046 0.000026 0.1623
ST6GALNAC5 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5
0.005612 0.017 0.0592
TLK2 Tousled-like kinase 2 0.012065 0.034 0.0462
ZBTB10 Zinc finger and BTB domain containing 10 0.038739 0.00088 0.1087
doi:10.1371/journal.pone.0020971.t001
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in CD45
2 cells and that of CIQB in CD45
+ cells using blood
samples from 20 melanoma patients and 20 healthy control
individuals by standard qRT-PCR analysis (Fig. 4). PLEK2
expression in CD45
2 cells was over 3-fold higher in melanoma
patients compared with healthy individuals (Fig. 4A). Although
sample numbers from each stage were small (n=3 to 8),
upregulation of PLEK2 expression in CD45
2 subset was detected
in blood samples of all stages of melanoma patients (Fig. 4B). On
the other hand, C1QB was upregulated in CD45
+ subset in
melanoma patients from all stages compared with healthy
individuals (Fig. 4C and 4D).
Discussion
Practical profiling methodology for biomarkers must be simple,
robust, reproducible, and easily accessible with adequate sensitivity
and specificity. There is a growing demand for the development of
new biomarkers using specimens that are easily and sequentially
available, i.e. peripheral blood, urine, or saliva. Peripheral whole
Table 2. Stepwise logistic regression (STEP) analysis signature models of melanoma.
Gene STEP p-value R square Gene STEP p-value R square
PLEK2 1 1.3E-15 0.5542 PLEK2 1 1.3E-15 0.5542
NEDD4L 1 1.6E-08 C1QB 2 2.5E-07 0.7314
PLXDC2 1 8.9E-08 PLXDC2 2 1.1E-05
C1QB 1 3.6E-07 TMOD1 2 1.5E-05
KCNK2 1 4.1E-07 TSPAN5 2 0.0001
XK 1 2.3E-06 GLRX5 2 0.00012
LARGE 1 5.6E-06 C20ORF108 2 0.00017
SIAH2 1 5.9E-06 GYPA 2 0.00029
IGF2BP2 1 1.3E-05 GYPB 2 0.0014
CNKSR2 1 1.4E-05 BLVRB 2 0.0017
NBEA 1 2.6E-05 IL1R2 2 0.0031
NUDT4 1 2.6E-05 PBX1 2 0.0062
SCN3A 1 3.4E-05 LARGE 2 0.0075
BPGM 1 3.8E-05 PLAUR 2 0.012
PTPRK 1 5.1E-05 SLC4A1 2 0.013
SLC4A1 1 6.0E-05 KCNK2 2 0.018
BLVRB 1 0.00015 SCN3A 2 0.02
LGALS3 1 0.00062 PTPRK 2 0.022
EDIL3 1 0.00082 CARD12 2 0.025
ZBTB10 1 0.00082 TLK2 2 0.031
GLRX5 1 0.00091 SLA 2 0.037
INPP4B 1 0.0013 RBMS1 2 0.038
TSPAN5 1 0.0015 CNKSR2 2 0.039
IL1R2 1 0.0018 CXCL16 2 0.045
TMOD1 1 0.0019 IRAK3 2 0.057
CHPT1 1 0.0034 RAB2B 2 0.084
PBX1 1 0.0056 NOTCH2 2 0.11
NUCKS1 1 0.007 F5 2 0.11
NEDD9 1 0.01 IGF2BP2 2 0.14
F5 1 0.012 CELSR1 2 0.14
TNS1 1 0.014 NUDT4 2 0.17
IRAK3 1 0.014 NEDD4L 2 0.17
ST6GALNAC5 1 0.016 BPGM 2 0.18
GYPA 1 0.019 LGALS3 2 0.18
GYPB 1 0.02 EDIL3 2 0.2
C20ORF108 1 0.026 PLEKHQ1 2 0.22
TLK2 1 0.035 ACOX1 2 0.24
CARD12 1 0.038 HECTD2 2 0.24
PLAUR 1 0.044 IL13RA1 2 0.25
doi:10.1371/journal.pone.0020971.t002
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information reservoir, and represents many systemic processes
including immune responses and cellular communications. By
using RNA stabilization tubes and the globin reduction technol-
ogy, we identified unique genes by microarray. By using high-
throughput qRT-PCR and STEP analysis, we identified unique
signature models differentially expressed in the blood of melanoma
patients.
Table 3. Two-gene models identified by STEP analysis.
Model R2
Detection rate of control
individuals (%)
Detection rate of melanoma
patients (%)
PLEK2-C1QB model 0.728 90.0 93.3
PLEK2-TMOD1 model 0.701 88.0 93.3
PLEK2-PLXDC2 model 0.701 88.0 93.3
PLEK2-TSPAN5 model 0.670 90.0 93.3
PLEK2-C20ORF108 model 0.662 92.0 86.7
PLEK2-GLRX5 model 0.661 90.0 88.9
PLEK2-GYPA model 0.650 88.0 91.1
PLEK2-SLC4A1 model 0.623 88.0 91.1
PLEK2-IL-1R2 model 0.621 88.0 88.9
PLEK2-BLVRB model 0.619 90.0 91.1
PLEK2-GYPB model 0.619 86.0 84.4
PLEK2-PBX1 model 0.611 88.0 86.7
PLEK2-PTPRK model 0.610 90.0 86.7
PLEK2-PLAUR model 0.603 84.0 84.4
PLEK2-CXCL16 model 0.603 88.0 88.9
PLEK2-CNKSR2 model 0.602 88.0 86.7
PLEK2-SCN3A model 0.602 86.0 86.7
PLEK2-LARGE model 0.602 88.0 84.4
PLEK2 (1-gene model) 0.560 84.0 86.7
doi:10.1371/journal.pone.0020971.t003
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0.00079 from microarray analysis and 4.2E-22 from high-
throughput qRT-PCR). This gene is highly upregulated in the
blood of melanoma patients from all stages, and even as a single
gene it classifies melanoma and control individuals accurately.
Furthermore, studies using fractionated blood cells revealed that
PLEK2 was almost exclusively expressed in CD45
2 cells,
indicating the importance of analyzing whole blood cells for
profiling blood transcriptomes. PLEK2 is a widely expressed
paralog of pleckstrin and was cloned in 1999 [49]. PLEK2 is
associated with cytoskeletal rearrangement and cell spreading, and
its overexpression results in the production of large lamellipodia,
cytoskeletal actin projections on the mobile edge of the cell
[49,50]. Lamellipodia are involved in angiogenesis in endothelial
cells and metastasis in melanoma cells [51,52,53,54]. It is thus
tempting to consider that increased expression of PLEK2 in blood
cells of melanoma patients may provide an environment for tumor
growth and metastasis by inducing the production of lamellipodia
in circulating cells.
C1QB, the second major classifier gene identified in our study,
is a component of the classical complement pathway and is
involved in the immune response after injury [55]. Deficiency of
C1q has been associated with autoimmune diseases such as lupus
erythematosus and glomerulonephritis [56], and upregulation of
C1QB was reported in infiltrating immune cells of stomach and
breast carcinoma [57] and in the brain of COX-2 transgenic mice
[58]. However, the function of C1QB in tumor biology and tumor
immunology is still largely unknown. In the current study, we
found that C1QB expression was significantly increased in the
leukocytes of melanoma patients from all stages. Furthermore, we
found that melanoma conditioned medium induced upregulation
of C1QB in CD45
+ cells (data not shown). The findings are in
agreement with our hypothesis that peripheral whole blood from
cancer patients may represent immune responses and cellular
communications altered by the presence of melanoma cells.
Further analysis of C1QB, PLEK2 and the other validated
biomarkers in fractionated blood cells will provide us more insight
into their functions and roles in melanoma development and
progression.
Single gene models had been traditionally used as biomarkers.
However, advances in high-throughput technologies, development
in biostatistics, bioinformatics and data visualization have enabled
the generation of molecular patterns (‘fingerprints’, ‘signatures’ or
‘classifiers’), which can be more robust and accurate as biomarkers
than single-molecule markers. Unlike single gene models, multi-
gene sets are less likely to be influenced by the variation in the
expression of one gene, since they use the entire set of genes to
classify samples. In the current study, we identified eighteen 2-
gene models to correctly classify melanoma patients from healthy
control individuals using STEP analysis. Of these, the PLEK2-
C1QB signature led to the best discrimination between melanoma
and healthy individuals. Noticeably, 2-gene signature models do
not always consist of two genes with the lowest p-value. For
example, PLEK2 was the gene with the lowest p-value but C1QB
did not have the second lowest p-value. In fact, NEDD4L, the gene
with the second lowest p-value, failed to be selected in the top 30
genes when PLEK2 was used as a starting gene and the
combination of PLEK2 and NEDD4L was not included in
eighteen 2-gene signatures. It is possible that PLEK2 and C1QB
may belong to independent pathways; therefore, changes in
expression of both genes may increase reliability in detecting
melanoma patients. Likewise, PLEK2 and NEDD4L may function
in closely related pathways, making this combination not stronger
compared with a single PLEK2 model. Indeed, we showed that
PLEK2 and C1QB represent processes in CD45
2 and CD45
+
subsets, respectively. These results indicate that signature genes
from different pathways or compartments would be more efficient
in distinguishing melanoma patients from healthy control
individuals.
Our microarray analysis also identified IL-4, Wnt, and Notch
signaling pathway in the blood from melanoma patients compared
with healthy control individuals. IL-4 is the key cytokine in humoral
and adaptive immunity. IL-4 has been shown to be significantly
upregulated in tumor infiltrating lymphocytes of cervical carcinoma
patient [59]. Th2 response, resulting in IL-4 production, was reported
to be enhanced in the peripheral blood of patients with bladder and
colorectal cancer compared with healthy controls [60]. Thus, our
results showing IL-4 signaling alternation in melanoma patients is
consistent with the notion that Th2 immune responses are associated
with tumor promotion and progression [61]. On the contrary, Wnt
and Notch signaling pathways are activated and expressed in cancer
cells, and are well known to play important roles in the development
and progression of cancers [62,63]. These results suggest that
melanoma development and survival is associated with changes both
in host stromal cells and tumor cells in the local tumor microenviron-
ment and systemic circulation in the blood. Furthermore, gene
ontology analysis revealed diverse responses (responses to stimulus,
stress and organism) and immune processes (immune process and
Figure 3. Expression of PLEK2 and C1QB in fractionated blood.
Freshly collected blood cells were fractionated into CD45
+ and CD45-
cells using whole blood CD45 kit, and analyzed by standard qRT-PCR.
Expression of PLEK2 and C1QB was normalized to the housekeeping
gene GAPDH. Data represent results from 6 healthy individuals. The
data are shown as the means 6 S.E. (n=6). **, p,0.01; ***, p,0.001
compared with CD45
2 subpopulation.
doi:10.1371/journal.pone.0020971.g003
Figure 2. Expression of PLEK2 and C1QB in whole blood of melanoma patients and healthy control individuals by high-throughput
qRT-PCR. A. Two-gene model of PLEK2 and C1QB. The level of gene expression was evaluated using healthy control (n=50), stage I melanoma
(n=5), stage II melanoma (n=8), stage III melanoma (n=11) and stage IV melanoma (n=21). PLEK2 for each subject (y-axis) is plotted against C1QB
(x-axis), and the best fit line demarcating healthy controls from melanoma patients is drawn. B. High-throughput qRT-PCR of PLEK2. The gene
expression was evaluated using healthy control (n=50), stage I melanoma (n=5), stage II melanoma (n=8), stage III melanoma (n=11) and stage IV
melanoma (n=21), and normalized to the level from healthy controls. C. High-throughput qRT-PCR of C1QB. The gene expression was evaluated
using healthy control (n=50), stage I melanoma (n=5), stage II melanoma (n=8), stage III melanoma (n=11) and stage IV melanoma (n=21), and
normalized to the level from healthy controls. The data are shown as means 6 S.E. (Sample numbers analyzed are included in parentheses). *, p,0.05;
**, p,0.01; ***, p,0.001 compared with healthy controls.
doi:10.1371/journal.pone.0020971.g002
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hypothesis that systemic processes including immune responses and
cellular communications can be detected in the blood of cancer
patients.
Developinganalyticalmethodologiesto detect molecularbiomarkers
in peripheral blood, which is easily accessible and noninvasive, is highly
valuable for the diagnosis and risk management of cancer patients. The
current study provides the first analysis of whole blood-based molecular
biomarkers for malignant melanoma. Our findings support the
hypothesis that gene expression profiles can define subsets of
individuals with melanoma. Furthermore, genes and signatures
identified in the current study are unique and have not been identified
in other studies of blood-based molecular biomarkers. In particular,
PLEK2, the strongest gene to classify melanoma patients, was
expressed in CD45
2 subsets, illustrating the importance of analyzing
whole blood cells for biomarker studies. It is not clear from these initial
studies what mechanisms are involved in the observed changes in gene
expression. The fact that the observed differences were with all stages of
melanoma suggests that these changes in peripheral blood cells can,
and do occur with small tumor burdens. This suggests that such
techniques could be used for both early detection of melanoma and
monitoring of patients undergoing treatment for residual disease.
Whole blood-based transcriptome profiles may also be used to support
staging patients, predicting prognosis and predicting response to
therapy in the future.
Supporting Information
Figure S1 Pathway analysis predicted IL-4 as one of the
differentially expressed signaling pathways between nor-
mal controls and melanomas. Significant pathways (p,0.05)
were analyzed using differentially expressed transcripts (p,0.05, fold
.1.8). Analysis was performed using pathway analysis tool from
GeneSpringGX 10.0. The figure represents IL-4 signaling pathway
where 20 differentially expressed genes were highlighted with blue
circles.
(TIF)
FigureS2 Identification of differentially expressedgenes
from 4 melanoma patients (stage IV, with no treatment,
M1–M4) and 6 healthy control individuals (C1–C6). A.
Heatmap of 63 selected transcripts with 1.8-fold or greater
significant differences between healthy controls and melanomas
and a high score by comparison replicates. Colored spots indicate
significant up- (red) or down- (blue) regulated genes. Sample tree
originated from the clustering of values with Euclidean distance
analyzed by GeneSpringGX 10.0. B. Transcripts showing 5.5-fold
or greater differences between healthy controls and melanomas.
Each color represents a single gene.
(TIF)
Table S1 Differentially expressed gene identified by
microarray analysis.
(DOC)
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